Throughout her career, Nicole has been a frequent speaker, presenting for Syracuse University's Maxwell School Transnational NGO Initiative, InterAction, the Ronald McDonald House Global Leadership Conference, the Global Impact Investing Network's Investor Forum, Mission Investors Exchange Institute, and National Association of Women Business Owners. Nicole also serves on the boards of RefuSHE and ChildFund International and previously served on the board of the Global Fund for Children. Having lived and wo ...

Core Insights - The article emphasizes a versatile investment strategy suitable for various investor profiles, including dividend investors, value seekers, and those looking for growth opportunities [1] Summary by Categories Investment Strategy - The investment strategy described is adaptable, catering to different types of investors, whether they focus on dividends, value propositions, or growth opportunities [1]

Core Insights - Terra Innovatum Global has been recognized for its thought leadership and commitment to sustainability, receiving a Special Mention for Sustainability at the 2025 UNCA Awards Gala [1][4] Company Overview - Terra Innovatum Global N.V. is a developer of micro-modular nuclear reactors, specifically the SOLO™ Micro-Modular Reactor, which aims to provide clean, affordable, and resilient baseload energy [3][7] - The SOLO™ reactor is designed to be deployable anywhere, starting at just 1 MWe, and can scale from 1 MWe to over 1 GW, facilitating the replacement of fossil-fuel plants [3][9] Technological Innovation - The SOLO™ reactor combines modularity, safety-by-design, and rapid deployability, enabling a new model for clean energy infrastructure that supports both developed and underserved regions [3][4] - It is engineered to provide a wide range of applications, including electricity, heating, cooling, water desalination, and the production of medical radioisotopes [9] Market Position and Future Plans - Terra Innovatum is fully funded with $131 million to deliver its first reactor, with regulatory approval targeted for late 2027 and commercialization expected in 2028 [4] - The company aims to address global energy shortages and promote energy equity, aligning its mission with the Sustainable Development Goals [4][8] Strategic Importance - The SOLO™ reactor is positioned to support critical infrastructure and enhance national resilience, particularly in the aftermath of natural disasters [3][4] - By providing reliable access to clean energy, the company contributes to economic growth, healthcare, education, and climate action, which are foundational to long-term community development [4][9]

Core Points - PesoRama Inc. is set to open its 31st JOi Dollar Plus store in Puebla, Mexico on December 21, 2025, marking a significant milestone in its expansion strategy [1][3] - The new store will be located approximately 6 km from the Historic Center of Puebla and will cover an area of 4,585 square feet within a major shopping mall [2] - The company aims to enhance accessibility for Mexican consumers and has plans for further expansion in high-density traffic areas [3] Company Overview - PesoRama operates under the JOi Dollar Plus brand, focusing on value dollar store retailing in Mexico, having launched operations in 2019 [5] - The company currently operates 30 stores, soon to be 31, offering a variety of merchandise including household goods, pet supplies, seasonal products, health and beauty items, and snacks [5] - PesoRama's strategy targets high-density, high-traffic locations to drive growth and success [5]

Core Viewpoint - Meta (META) is considered a "Strong Buy" despite a 10% decline in share price since early September [1] Group 1: Company Background - The analysis is conducted by a Chief Financial Officer (CFO) with over a decade of experience in finance, particularly in the oilfield and real estate industries [1] - The CFO has led numerous complex due diligence efforts and M&A transactions both domestically and internationally [1] Group 2: Investment Insights - The CFO has developed a keen interest in equity research and analysis of public companies, providing equity research services for a Dubai-based family office with over $20 million in assets under management [1] - The expertise in finance allows for valuable insights and recommendations for informed investment decisions [1] Group 3: Analytical Skills - The CFO prides on the ability to analyze financial statements, evaluate market trends, and identify key drivers of growth in different industries [1] - There is a strong passion for staying updated on the latest developments and trends in the equity research industry, with a commitment to continuing education and professional development [1]

The shares got caught up in the artificial-intelligence panic after hitting a record high earlier in the day. ...

Information in Investor's Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The information has been obtained from sources we believe to be reliable, but we make no guarantee as to its accuracy, timeliness, or suitability, including with respect to information that appears in closed captioning. Historical investment performances are no indication or guarantee of future success or perfo ...

WINNIPEG, Manitoba, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSXV:KNE) (the "Company", "Kane" or "Kane Biotech") announces that today it has completed its previously announced non-brokered private placement offering (the "Offering") of common shares of the Company ("Shares").At the closing of the Offering, Kane issued 14,000,000 Shares at a price of $0.05 per Share for gross proceeds of $700,000 to an insider of the Company.The net proceeds of the Offering will be used for working capital and ge ...

Core Points - Kane Biotech Inc. has completed a non-brokered private placement offering of common shares, issuing 14,000,000 shares at a price of $0.05 per share, resulting in gross proceeds of $700,000 [2] - The net proceeds from the offering will be allocated for working capital and general corporate purposes [2] - The transaction is classified as a "related party transaction" under Multilateral Instrument 61-101, and the company is exempt from formal valuation and minority approval requirements [3] Company Overview - Kane Biotech is focused on developing innovative wound care treatments that target biofilms, which contribute to antibiotic resistance in wounds, leading to serious clinical outcomes and high costs [5] - The company's products, including revyve® Antimicrobial Wound Gel and revyve® Antimicrobial Wound Gel Spray, have received US FDA 510(k) clearance and Health Canada approval [5]

The financial calendar for Schouw & Co. for 2026 is as follows: 5 March 2026Release of Annual Report 202516 April 2026Annual General Meeting21 April 2026Expected payment of dividend for 20251 May 2026Release of Q1 2026 interim report14 August 2026Release of Q2 2026 interim report6 November 2026Release of Q3 2026 interim report Resolution proposals from shareholders to be considered at the annual general meeting to be held on 16 April 2026 must be received by the company on or before Wednesday, 4 March 2026 ...